Servier, the manufacturer of strontium ranelate (Protelos®) has communicated the intention to cease supply of strontium in May 2017. In their notification it is advised that production and distribution would cease at the end of August 2017.

Protelos® is indicated in the treatment of severe osteoporosis in postmenopausal women and in adult men at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance.

Strontium ranelate has been the subject of several safety alerts over the years including life-threatening allergic reactions, venous thromboembolism and increased risk of heart problems. The manufacturer has now taken a strategic decision, for commercial reasons, to withdraw the product.

The worldwide and strategic decision has been taken for commercial reasons based on the following grounds:

- The restricted indication/limited use of Protelos/Osseor®,
- The continuous decrease of patients treated with Protelos/Osseor®.

Advice for healthcare professionals:

- Clinicians to be aware of this product being discontinued.
- Any patients who are currently prescribed this product will need to be reviewed and arrangements made to identify a suitable alternative.

Note: Strontium ranelate was taken off the ELMMB formulary, after the European Medicines Agency (EMA) review of the risks and benefits in 2014.

However, the latest EPACT data has identified some prescribing of strontium ranelate in East Lancashire GP practices

For further information, please contact the Medicines Management Teams on
01282 644801 (EL CCG) or 01254 282087 (BwD CCG)